Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER

Sachiyo Kawashima, Kaoru Kobayashi, Kaori Takama, Tomoaki Higuchi, Tomomi Furihata, Masakiyo Hosokawa and Kan Chiba
Drug Metabolism and Disposition June 2006, 34 (6) 1012-1018; DOI: https://doi.org/10.1124/dmd.106.009365
Sachiyo Kawashima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaoru Kobayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaori Takama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoaki Higuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomomi Furihata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masakiyo Hosokawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kan Chiba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

CYP2C9 and CYP2C19 are clinically important drug-metabolizing enzymes. The expression level of CYP2C9 is much higher than that of CYP2C19, although the factor(s) responsible for the difference between the expression levels of these genes is still unclear. It has been reported that hepatocyte nuclear factor 4α (HNF4α) plays an important role in regulation of the expression of liver-enriched genes, including P450 genes. Thus, we hypothesized that HNF4α contributes to the difference between the expression levels of these genes. Two direct repeat 1 (DR1) elements were located in both the CYP2C9 and CYP2C19 promoters. The upstream and downstream elements in these promoters had the same sequences, and HNF4α could bind to both elements in vitro. The transactivation levels of constructs containing two DR1 elements of the CYP2C9 promoter were increased by HNF4α, whereas those of the CYP2C19 promoter were not increased. The introduction of mutations into either the upstream or downstream element in the CYP2C9 gene abolished the responsiveness to HNF4α. We also examined whether HNF4α could bind to the promoter regions of the CYP2C9 and the CYP2C19 genes in vivo. The results of chromatin immunoprecipitation assays showed that HNF4α could bind to the promoter region of the CYP2C9 gene but not to that of the CYP2C19 promoter in the human liver. Taken together, our results suggest that HNF4α is a factor responsible for the difference between the expression levels of CYP2C9 and CYP2C19 in the human liver.

Footnotes

  • This work was supported by a grant-in-aid (17790112) for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and a grant-in-aid from the Ministry of Health, Labor, and Welfare of Japan (Research in Regulatory Science of Pharmaceutical and Medical Devices).

  • A preliminary account of this work was presented at the International Society for the Study of Xenobiotics (ISSX) meeting held on August 29 to September 2, 2004 in Vancouver, Canada.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.106.009365.

  • ABBREVIATIONS: P450, cytochrome P450; HNF4α, hepatocyte nuclear factor 4α; DR1, direct repeat 1; kb, kilobase(s); kbp, kilobase pair(s); EMSA, electrophoretic mobility shift assay; ChIP, chromatin immunoprecipitation; PCR, polymerase chain reaction; WT, wild-type; MT, mutated.

    • Received January 18, 2006.
    • Accepted March 10, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (6)
Drug Metabolism and Disposition
Vol. 34, Issue 6
1 Jun 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER

Sachiyo Kawashima, Kaoru Kobayashi, Kaori Takama, Tomoaki Higuchi, Tomomi Furihata, Masakiyo Hosokawa and Kan Chiba
Drug Metabolism and Disposition June 1, 2006, 34 (6) 1012-1018; DOI: https://doi.org/10.1124/dmd.106.009365

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER

Sachiyo Kawashima, Kaoru Kobayashi, Kaori Takama, Tomoaki Higuchi, Tomomi Furihata, Masakiyo Hosokawa and Kan Chiba
Drug Metabolism and Disposition June 1, 2006, 34 (6) 1012-1018; DOI: https://doi.org/10.1124/dmd.106.009365
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sex- and lifestyle-related factors affect hepatic CYP levels
  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics